Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)

NCT04140526 is registered in ClinicalTrials.gov with OncoC4, Inc. as lead sponsor.

NCT NCT04140526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04140526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Lead sponsor
OncoC4, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 16, 2020
Completion date
December 31, 2027
Enrollment
733 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, advanced solid tumor, cervical cancer, esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, metastatic head and neck carcinoma, metastatic melanoma, metastatic prostate cancer, metastatic renal cell carcinoma, non small cell lung cancer, ovarian cancer, pancreas cancer, salivary gland cancer, sarcomas, small cell lung cancer, urothelial carcinoma